Cargando…
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) is an important treatment for ovarian cancer. A certain portion of cisplatin exits the body via the perfusate at the end of HIPEC, so full-dose utilization cannot be achieved. Herein, we sought to explore how much cisplatin is actually ut...
Autores principales: | Wang, Wu-yun, Wu, Miao-fang, Wu, Dong-bing, Wang, Li-juan, Li, Hui, Lin, Zhong-qiu, Li, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796576/ https://www.ncbi.nlm.nih.gov/pubmed/33419462 http://dx.doi.org/10.1186/s13048-021-00764-6 |
Ejemplares similares
-
A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
por: Chan, Chui-ying, et al.
Publicado: (2021) -
Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
por: Wu, Tao, et al.
Publicado: (2018) -
The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
por: Glennon, Kate, et al.
Publicado: (2021) -
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020) -
Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience
por: Gao, Tian, et al.
Publicado: (2019)